Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia

Naveen Premnath; Yazan F. Madanat

doi:10.3390/cancers15112958

Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia

Naveen Premnath, Yazan F. Madanat

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need. Basic science and clinical investigators across the world have been working on many new and old molecule formulations and combination strategies to improve outcomes in this disease. In this review, we discuss select promising novel agents in various stages of clinical development for patients with AML.

Original language	English (US)
Article number	2958
Journal	Cancers
Volume	15
Issue number	11
DOIs	https://doi.org/10.3390/cancers15112958
State	Published - Jun 2023

Keywords

AML
NK cell
cell therapy
immunotherapy
leukemia
menin

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers15112958

Cite this

@article{9fde5623c90b4e8386b2c81e3ffbe2f9,

title = "Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia",

abstract = "Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need. Basic science and clinical investigators across the world have been working on many new and old molecule formulations and combination strategies to improve outcomes in this disease. In this review, we discuss select promising novel agents in various stages of clinical development for patients with AML.",

keywords = "AML, NK cell, cell therapy, immunotherapy, leukemia, menin",

author = "Naveen Premnath and Madanat, {Yazan F.}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = jun,

doi = "10.3390/cancers15112958",

language = "English (US)",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "11",

}

TY - JOUR

T1 - Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia

AU - Premnath, Naveen

AU - Madanat, Yazan F.

PY - 2023/6

Y1 - 2023/6

N2 - Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need. Basic science and clinical investigators across the world have been working on many new and old molecule formulations and combination strategies to improve outcomes in this disease. In this review, we discuss select promising novel agents in various stages of clinical development for patients with AML.

AB - Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need. Basic science and clinical investigators across the world have been working on many new and old molecule formulations and combination strategies to improve outcomes in this disease. In this review, we discuss select promising novel agents in various stages of clinical development for patients with AML.

KW - AML

KW - NK cell

KW - cell therapy

KW - immunotherapy

KW - leukemia

KW - menin

UR - http://www.scopus.com/inward/record.url?scp=85161295991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85161295991&partnerID=8YFLogxK

U2 - 10.3390/cancers15112958

DO - 10.3390/cancers15112958

M3 - Review article

C2 - 37296920

AN - SCOPUS:85161295991

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 11

M1 - 2958

ER -

Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this